“Copay offset programs [offered by brand-name drugmakers to compete with generics] mitigate the effectiveness of our tiered benefit design programs and [are] going against what we’re trying to accomplish for our members’ health and for employers.”
— Peter Clagett, vice president of pharmaceutical strategies and PBM oversight for WellPoint, Inc., told AIS’s Drug Benefit News.
No comments:
Post a Comment